Is Regulatory Approval The Happy Ever After? What Comes After the 'Regulatory Finish Line'

In regulatory affairs, we love a finish line. Years of development, a dossier thick enough to prop open a door, rounds of queries, and then, finally, the approval letter; the door to the market finally opened.

But after a week at PharmaReg AfriSummit 2026, I have started to wonder whether, from the patient's side, we are sometimes popping the champagne at the halfway mark.

Don't get me wrong, the Summit was genuinely encouraging. Regulators, industry and technology partners in the same rooms, talking about harmonization, reliance, digital regulatory systems, stronger national authorities and cutting out duplication. And for once, the tone wasn't "wouldn't it be nice if…". It was "here's how we actually make this work."

That matters. For a manufacturer juggling a dozen markets, predictability matters. For a regulator with a growing queue and a not-so-growing team, reliance matters. And for a patient waiting on a medicine, every month shaved off redundant reviews matters a great deal.

I had the privilege of moderating a panel on digital regulatory transformation, and there was no shortage of ambition in the room.

But somewhere between the panels, the corridor conversations and my third cup of conference coffee, one question kept nagging at me:

What comes after the medicine is approved? And do we really appreciate what it takes to get it to where it is needed?

Approval is a milestone, not a destination. Or, put more simply: approval is not arrival.

Registered, authorized… and nowhere to be found

A medicine can be scientifically sound, quality-assured and fully authorized for a market, and still not be on the shelf when someone needs it.

The registration might be sitting there while nobody actually supplies the product. The manufacturer can't see enough demand to bother. The buyer needs it but doesn't have the cash this month. A document is missing. The import permit is 'being processed.' The shipment is stuck at the border, where customs agents might let it sit above 30C for days. The truck carrying the medicine lost its cold chain...

And as anyone who has ever tracked an international shipment knows, 'in transit' can feel less like a logistics status and more like a philosophical concept.

Here's the bit that really gets me. Most of us can track a takeaway order down to the exact roundabout where the rider is stuck. Yet for many essential medicines, the honest answer to 'where is it?' is still a phone call, a WhatsApp message and a fair amount of hope.

The patient's test is much simpler than ours

Those of us in regulatory affairs spend a lot of time asking whether a product can legally enter a market. Patients use a far less technical test:

"Is the medicine here when I need it?"

No patient has ever walked into a hospital and asked whether their quality-assured antibiotic benefited from an efficient reliance pathway. We might quietly celebrate that over a cup of tea. They just want the box on the shelf.

None of this is a knock on regulation. Quite the opposite. Regulation is the starting point for anyone to trust any health product at all. The real question is whether that trust survives the rest of the trip.

On paper, a success

I was reminded of this by a case we came across in our regulatory work. A quality-assured medicine had been procured and shipped. Legitimate supplier. Documentation in order. Procurement done. Shipment physically arrived.

Every box ticked.

Except that somewhere along the way, the product had spent time at temperatures outside its stability conditions. The stock went on hold while the impact on quality was assessed.

Approved. Bought. Shipped. Arrived. And still not available to a single patient.

That's when it properly sank in for me: access isn't about moving products. It's about moving trusted products through trusted systems.

Regulatory trust has to travel with the medicine. It can't stay behind at the regulator's office, framed on the wall.

That means the right supplier, the right product, the right documents, the right market, the right storage and transport, and enough visibility along the way to spot trouble before it becomes a patient's problem.

We have enough dashboards

This is why the next chapter of digital transformation in healthcare has to be about more than digitising forms. It has to connect information that currently lives in separate silos (and occasionally in someone's personal spreadsheet called "FINAL_v7_actual_final").

Imagine seeing regulatory status alongside real market demand. Supplier qualification alongside procurement. Product documents alongside the transaction. Import requirements alongside the shipment. Delivery performance alongside next quarter's purchasing decisions.

The point isn't another dashboard. We have plenty. Some of them are very beautiful. The point is seeing something early enough to make a better decision.

Visibility turns transactions into information. Over time, information becomes intelligence. And intelligence changes behaviour.

And then, of course, there's the money

A medicine can be approved, in stock and fairly priced, and still go nowhere because the buyer can't pay today. At this point, we often don't have a financing problem alone, we have an access problem wearing a finance badge.

The medicine doesn't care about our org chart

We like to divide access into tidy boxes and hand each box to a different team, and hope it all joins up at the end.

Real life is rarely that cooperative.

The medicine moves through every one of those systems, whether they're talking to each other or not. This is where I think the wider pharmaceutical ecosystem can complement what regulators are already doing. The rest of us have to build systems that carry those standards into real transactions and real supply chains, so nobody is scrambling to assemble a compliance folder when the shipment is already sitting at the port.

At Axmed, that's how we work: connecting demand with quality supply, bringing visibility to procurement, building regulatory requirements into the transaction, and following the product through delivery. But the idea is much bigger than any one company or platform. It's about markets where regulation, procurement, financing, logistics and data pull in the same direction instead of holding separate meetings.

So, what happens after approval?

The progress on harmonisation, reliance and digital transformation across Africa deserves real credit, and real acceleration. Regulators are finding ways to work smarter and share more without lowering the bar that protects patients. That is genuine progress.

But as those systems get stronger, let's keep asking what happens on the other side of the approval letter.

Can manufacturers see the demand? Can buyers reach quality-assured supply? Can the purchase be financed? Does compliance stay visible as the product moves? Can we catch problems before they turn into stockouts, delays or quality failures?

And most importantly, can we follow the medicine all the way to the person it was meant for?

Because the real measure of access isn't the registration certificate, the purchase order or even the shipment. Those are milestones, and important ones. But nobody ever got better from a milestone.

Approval opens the door. Access is the entire journey through it. And maybe the next big opportunity in African healthcare isn't just getting more medicines through that door, but being able to see, trust and support every step until they reach the people who need them.